HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Bradford P. Blakeman Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blakeman, B. P. Search for Related Content PubMed Articles by Blakeman, B. P. Related Collections Related Article

Ann Thorac Surg 1997;64:132-133
© 1997 The Society of Thoracic Surgeons

---

Invited Commentary

Invited Commentary

Cardiac Surgical Associates, 1325 N Highland, Aurora, IL 60506

The first 20% of the full text of this article appears below.

See also page 129.

The most impressive message in this article is summarized by Figure 1. It shows that at 16 months, almost 50% of the patients with end-stage renal disease (ESRD) are dead. This is the same piece of data we found from our ESRD group of patients in 1988 that included coronary artery bypass graft and valve replacement patients. With this information in mind, the valve of choice would be the biologic valve to prevent possibilities of bleeding. One must remember . . . [Full Text of this Article]

Related Article

Results of Valve Replacement With Mechanical and Biological Prostheses in Chronic Renal Dialysis Patients

John C. Lucke, Ravi N. Samy, B. Zane Atkins, Scott C. Silvestry, James M. Douglas, Jr, Steven J. Schwab, Walter G. Wolfe, and Donald D. Glower
Ann. Thorac. Surg. 1997 64: 129-132. [Abstract] [Full Text]